Bambusa Therapeutics co-founder reports six options

Q: What stock options did BBTX's Minh Quoc Thang Ho report?

Ho reported six direct option positions: four covering 103,891, 141,290, 23,172 and 15,448 common shares at $0.3400 per share, expiring December 18, 2034; one covering 128,503 shares at $1.8400, expiring August 15, 2035; and one covering 261,079 shares at $13.5700, expiring September 17, 2036.

Option vesting depends on continued employment; some schedules are tied to FDA or comparable non-U.S. regulator trial approvals.

Accepted by SEC EDGAR 10/29/2026 - 04:27 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bambusa Therapeutics, Inc. (BBTX) reports that its Co-Founder and Chief Development Officer, Minh Quoc Thang Ho, directly holds six stock-option positions on common shares. Four positions cover 103,891, 141,290, 23,172 and 15,448 shares at an exercise price of $0.3400 each, expiring December 18, 2034; another covers 128,503 shares at $1.8400, expiring August 15, 2035; and the sixth covers 261,079 shares at $13.5700, expiring September 17, 2036. Vesting is subject to continued employment.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ho Minh Quoc Thang

Role See remarks

Type	Security	Shares	Price	Value
Holding	Stock Option (right to buy) ^F1	--	--	--
Holding	Stock Option (right to buy) ^F2	--	--	--
Holding	Stock Option (right to buy) ^F3	--	--	--
Holding	Stock Option (right to buy) ^F4	--	--	--
Holding	Stock Option (right to buy) ^F5	--	--	--
Holding	Stock Option (right to buy) ^F6	--	--	--

Holdings: Stock Option (right to buy) — 673,383 contracts (Direct)

Footnotes (6)

F1. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 15, 2024.
F2. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 15, 2024.
F3. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, 1/48th of such shares on each monthly anniversary of the date that the Company obtains its first first-in-human trial approval from the FDA or a comparable non-U.S. regulatory body (which was obtained on January 31, 2025).
F4. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, 1/48th of the total number of such shares on each monthly anniversary of the date that the Company obtains its second first-in-human trial approval from the FDA or a comparable non-U.S. regulatory body (which was obtained on May 6, 2025).
F5. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean June 19, 2025.
F6. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 18, 2026.

Key Figures

Underlying common shares: 103,891 shares Underlying common shares: 141,290 shares Underlying common shares: 23,172 shares +3 more

6 metrics

Underlying common shares 103,891 shares Exercise price $0.3400; expiration December 18, 2034

Underlying common shares 141,290 shares Exercise price $0.3400; expiration December 18, 2034

Underlying common shares 23,172 shares Exercise price $0.3400; expiration December 18, 2034

Underlying common shares 15,448 shares Exercise price $0.3400; expiration December 18, 2034

Underlying common shares 128,503 shares Exercise price $1.8400; expiration August 15, 2035

Underlying common shares 261,079 shares Exercise price $13.5700; expiration September 17, 2036

Key Terms

Stock Option (right to buy), Vesting Commencement Date, first-in-human trial approval

3 terms

Stock Option (right to buy) technical

"Stock Option (right to buy)"

Vesting Commencement Date technical

""Vesting Commencement Date" shall mean April 15, 2024."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

first-in-human trial approval regulatory

"first-in-human trial approval from the FDA"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did BBTX's Minh Quoc Thang Ho report?

Ho reported six direct option positions: four covering 103,891, 141,290, 23,172 and 15,448 common shares at $0.3400 per share, expiring December 18, 2034; one covering 128,503 shares at $1.8400, expiring August 15, 2035; and one covering 261,079 shares at $13.5700, expiring September 17, 2036.

How do Minh Quoc Thang Ho's BBTX options vest?

All six options are subject to Ho remaining an employee through each applicable vesting date. Three schedules vest 25% at the first anniversary and 1/48 monthly thereafter, with commencement dates April 15, 2024, June 19, 2025 and September 18, 2026. The other three vest 1/48 monthly from April 15, 2024 or from first-in-human trial approvals obtained January 31, 2025 and May 6, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ho Minh Quoc Thang

(Last)

(First)

(Middle)

C/O BAMBUSA THERAPEUTICS, INC.

22 BOSTON WHARF ROAD, FLOOR 7

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Bambusa Therapeutics, Inc. [ BBTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	12/18/2034	Common Stock	103,891	$0.34	D
Stock Option (right to buy)	⁽²⁾	12/18/2034	Common Stock	141,290	$0.34	D
Stock Option (right to buy)	⁽³⁾	12/18/2034	Common Stock	23,172	$0.34	D
Stock Option (right to buy)	⁽⁴⁾	12/18/2034	Common Stock	15,448	$0.34	D
Stock Option (right to buy)	⁽⁵⁾	08/15/2035	Common Stock	128,503	$1.84	D
Stock Option (right to buy)	⁽⁶⁾	09/17/2036	Common Stock	261,079	$13.57	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 15, 2024.

2. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 15, 2024.

3. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, 1/48th of such shares on each monthly anniversary of the date that the Company obtains its first first-in-human trial approval from the FDA or a comparable non-U.S. regulatory body (which was obtained on January 31, 2025).

4. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, 1/48th of the total number of such shares on each monthly anniversary of the date that the Company obtains its second first-in-human trial approval from the FDA or a comparable non-U.S. regulatory body (which was obtained on May 6, 2025).

5. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean June 19, 2025.

6. Subject to the Reporting Person continuing to be an Employee (as defined in the Issuer's 2024 Stock Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 18, 2026.

Remarks:

Co-Founder and Chief Development Officer; Exhibit 24 - Power of Attorney

	/s/ Jonathan I. Lieber, as attorney-in-fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR